☆ 4.4 Review

ABO Blood Group and the Risk of Thrombosis in Cancer Patients: A Mini-Review

SEMINARS IN THROMBOSIS AND HEMOSTASIS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Venous thromboembolism and radiation therapy: The final radiation-induced thrombosis study analysis

Elisabeth Daguenet et al.

Summary: A prospective study on newly diagnosed cancer patients receiving curative radiotherapy found a 2% incidence rate of VTE, with half occurring during radiotherapy and half in patients receiving chemotherapy. Most patients received monotherapy without specific identified risk factors for thromboprophylaxis. The study provides important insights for future research and recommendations for frail patients.

CANCER MEDICINE (2022)

Add to Collection

Article Hematology

ABO blood group type and risk of venous thromboembolism in patients with cancer

Cornelia Englisch et al.

Summary: Non-O blood type is associated with increased VTE risk in cancer patients, particularly after 3 months and in patients with intermediate and low-risk tumor types.

BLOOD ADVANCES (2022)

Add to Collection

Article Peripheral Vascular Disease

Association between ABO blood group and venous thrombosis related to the peripherally inserted central catheters in cancer patients

Guodong Wang et al.

Summary: A retrospective analysis of cancer patients who underwent PICC catheterization revealed a higher risk of PICC-related thrombosis in patients with non-O blood type compared to those with blood type O. Other risk factors for thrombosis included a history of venous thrombosis, tumor category, arm circumference, and insertion attempts.

JOURNAL OF VASCULAR ACCESS (2021)

Add to Collection

Article Hematology

Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer

Yohei Hisada et al.

Summary: This study investigated the association of active Lys-PG in plasma and VTE in pancreatic cancer patients, as well as the impact of human pancreatic tumors expressing Lys-PG on venous thrombus resolution in mice. The results suggest that Lys-PG may contribute to the development of VTE in pancreatic cancer.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease

Paula D. James et al.

Summary: These evidence-based guidelines on von Willebrand disease (VWD) provide 11 key recommendations for clinicians and patients, covering various aspects of VWD diagnosis, including the use of bleeding-assessment tools, diagnostic assays, laboratory cutoffs, and genetic testing versus phenotypic assays. Future critical research priorities are also identified.

BLOOD ADVANCES (2021)

Add to Collection

Review Hematology

Cancer Therapy-Associated Thrombosis

Steven P. Grover et al.

Summary: Cancer patients are at a higher risk of arterial and venous thrombotic events compared to the general population, with factors such as cancer site and stage, treatment-related factors, and cytotoxic effects of chemotherapeutic agents contributing to this increased risk. Despite advancements in targeted therapies, some anticancer agents still carry a risk of thrombosis, necessitating a better understanding of the mechanisms involved to develop effective treatment strategies.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)

Add to Collection

Article Hematology

Venous thromboembolism in cancer patients: a population-based cohort study

F. Mulder et al.

Summary: Over the past decade, the incidence of venous thromboembolism (VTE) in cancer patients may have changed due to novel cancer therapies, improved survival, and high-resolution imaging. The risk of VTE in cancer patients is steadily increasing and is ninefold higher than in the general population.

BLOOD (2021)

Add to Collection

Review Medicine, General & Internal

The Impact of ABO Blood Type on Developing Venous Thromboembolism in Cancer Patients: Systematic Review and Meta-Analysis

Fumihiko Urabe et al.

Summary: The impact of ABO blood type on the development of venous thromboembolism in cancer patients is controversial. This systematic review and meta-analysis found that non-O blood type is associated with an increased risk of venous thromboembolism in cancer patients, especially in post-operative urological cancer patients.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Oncology

External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model

Alex C. Spyropoulos et al.

ONCOLOGIST (2020)

Add to Collection

Review Hematology

The relationship between ABO blood group, von Willebrand factor, and primary hemostasis

Soracha E. Ward et al.

BLOOD (2020)

Add to Collection

Article Hematology

ABO blood group, glycosyltransferase activity and risk of venous thromboembolism

Manal Ibrahim-Kosta et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Article Hematology

Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy

Budi Setiawan et al.

THROMBOSIS JOURNAL (2020)

Add to Collection

Review Respiratory System

Cancer-associated thrombosis: the when, how and why

Caio J. Fernandes et al.

EUROPEAN RESPIRATORY REVIEW (2019)

Add to Collection

Article Hematology

Prothrombotic genotypes and risk of venous thromboembolism in cancer

Olga V. Gran et al.

THROMBOSIS RESEARCH (2018)

Add to Collection

Article Oncology

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study

Konstantinos Syrigos et al.

ONCOLOGIST (2018)

Add to Collection

Review Oncology

Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment

Norbaini Binti Abdol Razak et al.

CANCERS (2018)

Add to Collection

Article Oncology

Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer

Xia Liu et al.

ONCOLOGY LETTERS (2017)

Add to Collection

Article Hematology

ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer

M. Pepin et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)

Add to Collection

Article Oncology

ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer

Donghui Li et al.

CANCER MEDICINE (2015)

Add to Collection

Review Hematology

von Willebrand factor and cancer: A renewed interest

Massimo Franchini et al.

THROMBOSIS RESEARCH (2013)

Add to Collection

Review Medical Laboratory Technology

ABO blood group, hypercoagulability, and cardiovascular and cancer risk

Massimo Franchini et al.

CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2012)

Add to Collection

Article Hematology

Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis

Nicholas L. Smith et al.

BLOOD (2011)

Add to Collection

Article Oncology

Breast Cancer-Associated Thrombotic Microangiopathy

Anne C. Regierer et al.

BREAST CARE (2011)

Add to Collection

Article Hematology

Development and validation of a predictive model for chemotherapy-associated thrombosis

Alok A. Khorana et al.

BLOOD (2008)

Add to Collection

Article Hematology

Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice

V Terraube et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)

Add to Collection

Article Hematology

ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis

M Bohm et al.

THROMBOSIS RESEARCH (2003)

Add to Collection

Article Medicine, General & Internal

Relative impact of risk factors for deep vein thrombosis and pulmonary embolism - A population-based study

JA Heit et al.

ARCHIVES OF INTERNAL MEDICINE (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.